Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Mol Ther Methods Clin Dev ; 32(3): 101286, 2024 Sep 12.
Artículo en Inglés | MEDLINE | ID: mdl-39070292

RESUMEN

Although the last decade has seen tremendous progress in drugs that treat cystic fibrosis (CF) due to mutations that lead to protein misfolding, there are approximately 8%-10% of subjects with mutations that result in no significant CFTR protein expression demonstrating the need for gene editing or gene replacement with inhaled mRNA or vector-based approaches. A limitation for vector-based approaches is the formation of neutralizing humoral responses. Given that αCD20 has been used to manage post-transplant lymphoproliferative disease in CF subjects with lung transplants, we studied the ability of αCD20 to module both T and B cell responses in the lung to one of the most immunogenic vectors, E1-deleted adenovirus serotype 5. We found that αCD20 significantly blocked luminal antibody responses and efficiently permitted re-dosing. αCD20 had more limited impact on the T cell compartment, but reduced tissue resident memory T cell responses in bronchoalveolar lavage fluid. Taken together, these pre-clinical studies suggest that αCD20 could be re-purposed for lung gene therapy protocols to permit re-dosing.

2.
mBio ; 15(1): e0146423, 2024 Jan 16.
Artículo en Inglés | MEDLINE | ID: mdl-38117035

RESUMEN

IMPORTANCE: Our study reveals the potential of precision-cut lung slices as an ex vivo platform to study the growth/survival of Pneumocystis spp. that can facilitate the development of new anti-fungal drugs.


Asunto(s)
Antiinfecciosos , Pneumocystis , Neumonía por Pneumocystis , Pulmón/microbiología , Neumonía por Pneumocystis/microbiología
3.
Methods Mol Biol ; 2667: 169-179, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37145284

RESUMEN

Pneumocystis jirovecii causes pneumonia in immunocompromised patients. A major challenge in drug susceptibility testing and in understanding host/pathogen interactions is that Pneumocystis spp. are not viable in vitro. Continuous culture of the organism is not currently available, and therefore, developing new drug targets is very limited. Due to this limitation, mouse models of Pneumocystis pneumonia have proven to be an invaluable resource to researchers. In this chapter, we provide an overview of selected methods used in mouse models of infection including, in vivo Pneumocystis murina propagation, routes of transmission, genetic mouse models available, a P. murina life form-specific model, a mouse model of PCP immune reconstitution inflammatory syndrome (IRIS), and the experimental parameters associated with these models.


Asunto(s)
Mycobacterium tuberculosis , Pneumocystis carinii , Neumonía por Pneumocystis , Animales , Ratones , Pruebas de Sensibilidad Microbiana , Pneumocystis carinii/genética , Neumonía por Pneumocystis/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA